91ÉçÇø

Jacques Archambault

Academic title(s): 

Professor, Department of Microbiology and Immunology

Jacques Archambault
Contact Information
Address: 

Duff Medical Building
3775 University St., Room D22
Montreal, QC H3A 2B4

Email address: 
jacques.archambault2 [at] mcgill.ca
Phone: 
514-398-3485
Department: 
Microbiology and Immunology
Area(s): 
Infectious Diseases
Microbiology
Biography: 

Dr. Archambault is a professor in the department of Microbiology and Immunology and an associate member of the division of Experimental Medicine since august 2016. Prior to joining 91ÉçÇø, Dr. Archambault was the director of the Molecular Virology laboratory at the Institut de recherches cliniques de Montreal (IRCM) from 2003-2016, and former coordinator of the HPV and HIV research programs at Boehringer Ingelheim from 1996-2003.

Current research: 

My laboratory is interested in the molecular biology and pathogenesis of human papillomaviruses (HPVs) and polyomaviruses (HPyVs), two families of small DNA tumor viruses that are widespread in the human population and cause significant diseases. While oncogenic HPV types are the cause of most anogenital and oropharyngeal cancers, reactivation of HPyVs in immunosuppressed individuals can lead to different pathologies including viral-induced nephropathy in kidney transplant patients (BKPyV), progressive multifocal encephalopathy in multiple sclerosis patients under immunosuppressive drug therapy (JCPyV), and Merkel cell carcinoma (MCPyV), a rare but very aggressive type of skin cancer, to name a few. My laboratory has a particular interest in elucidating the mechanism used by these viruses to replicate their circular double-stranded DNA genome as episomes in the nucleus of infected cells. Functional genomics, proteomics and chemical biology approaches are used to identify cellular pathways targeted by these viruses. Another important aspect of our research is the development of high-throughput assays for the screening of small molecule inhibitors of viral replication as potential drug leads for the treatment of HPV and HPyV associated diseases. 

Selected publications: 

Back to top